0000000001300829

AUTHOR

Piscaglia F.

showing 4 related works from this author

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

2014

Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to …

Malemedicine.medical_specialtyPediatricsCarcinoma HepatocellularTime FactorsHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIADiseaseGastroenterologyBiasInternal medicineOverall survivalmedicineHumansEarly Detection of CancerAgedEstimationSurveillanceHepatologybusiness.industryLiver Neoplasmsmedicine.diseasedigestive system diseasesLead time biasCirrhosisHepatocellular carcinomaFemalebusinessLead-time biasFollow-Up Studies
researchProduct

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

SIUMB recommendations for focal pancreatic lesions

2020

AbstractContrast-enhanced ultrasonography (CEUS) is increasingly being performed in Italy and Europe, particularly in the field of hepato-gastroenterology. Initially, it was mainly carried out to characterize focal hepatic lesions, but, since then, numerous studies have demonstrated its efficacy in the differential diagnosis of focal pancreatic pathologies (D’Onofrio et al. in Expert Rev Med Devices 7(2):257–273, 2010; Vidili et al. in J Ultrasound 22(1):41–51, 2019). The purpose of this paper is to provide Italian Medical Doctors with recommendations and thereby practical guidelines on the management of these patients. The present paper reports the final conclusions reached by the SIUMB gu…

Image-Guided Biopsymedicine.medical_specialtyPercutaneousContrast Media030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciencesPancreatic cystic lesion0302 clinical medicinePancreatic cancerCEUS; Contrast-enhanced ultrasound; Pancreas; Pancreatic adenocarcinoma; Pancreatic biopsy; Pancreatic cancer; Pancreatic cancer; Pancreatic cystic lesions; Ultrasound; Diagnosis Differential; Humans; Image-Guided Biopsy; Pancreatic Cyst; Pancreatic Neoplasms; Ultrasonography; Contrast MediaDiagnosisCEUS Ultrasound Contrast-enhanced ultrasound Pancreas Pancreatic adenocarcinoma Pancreatic cystic lesions Pancreatic biopsy Pancreatic cancerUltrasoundInternal MedicinemedicineHumansPancreaRadiology Nuclear Medicine and imagingPancreatic biopsyPancreasCEUS; Contrast-enhanced ultrasound; Pancreas; Pancreatic adenocarcinoma; Pancreatic biopsy; Pancreatic cancer; Pancreatic cancer; Pancreatic cystic lesions; UltrasoundUltrasonography030219 obstetrics & reproductive medicinebusiness.industryGeneral surgeryPancreatic biopsyGeneral MedicineGuidelinePancreatic cancermedicine.diseasePancreatic Neoplasmsmedicine.anatomical_structureDifferentialCEUSOriginal ArticleCEUS; Contrast-enhanced ultrasound; Pancreas; Pancreatic adenocarcinoma; Pancreatic biopsy; Pancreatic cancer; Pancreatic cystic lesions; UltrasoundUltrasonographyDifferential diagnosisPancreatic CystbusinessPancreasPancreatic adenocarcinomaContrast-enhanced ultrasoundContrast-enhanced ultrasoundPancreatic cystic lesions
researchProduct

Supplementary Material for: Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

2021

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated. Methods: We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy. Results: Ninety-six patients from 15 centres received cabozantinib. All patients had preserved liver function (Child-Pugh A), mostly …

researchProduct